PTHS.US Pelthos Therapeutics Inc.

Healthcare Pharmaceuticals USA Stocks
6.84 USD
Close of Nov 18, 2026
6.76 31.62
Market cap
USD 26.9M
P/E
-
P/B
2.86x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PTHS.US undervalued?

Graham number

The Graham number of Pelthos Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pelthos Therapeutics Inc. fundamental analysis

No fundamental analysis for Pelthos Therapeutics Inc. yet.

Pelthos Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE…

Full company profile